Melatonin as a Coadjuvant in the Treatment of Patients with Fibromyalgia

González-Flores, David ; López-Pingarrón, Laura (Universidad de Zaragoza) ; Castaño, María Yolanda ; Gómez, María Ángeles ; Rodríguez, Ana B ; García, Joaquín J (Universidad de Zaragoza) ; Garrido, María

Resumen: Fibromyalgia syndrome (FMS) is a chronic widespread pain syndrome that is accompanied by fatigue, sleep disturbances, anxiety, depression, lack of concentration, and neurocognitive impairment. As the currently available drugs are not completely successful against these symptoms and frequently have several side effects, many scientists have taken on the task of looking for nonpharmacological remedies. Many of the FMS-related symptoms have been suggested to be
associated with an altered pattern of endogenous melatonin. Melatonin is involved in the regulation of several physiological processes, including circadian rhythms, pain, mood, and oxidative as well as immunomodulatory balance. Preliminary clinical studies have propounded that the administration of different doses of melatonin to patients with FMS can reduce pain levels and ameliorate mood and sleep disturbances. Moreover, the total antioxidant capacity, 6-sulfatoxymelatonin and urinary cortisol levels, and other biological parameters improve after the ingestion of melatonin. Recent investigations have proposed a pathophysiological relationship between mitochondrial dysfunction, oxidative stress, and FMS by looking at certain proteins involved in mitochondrial homeostasis according to the etiopathogenesis of this syndrome. These improvements exert positive effects on the quality of life of FMS patients, suggesting that the use of melatonin as a coadjuvant may be a successful strategy for the management of this syndrome.

Idioma: Inglés

DOI: 10.3390/biomedicines11071964

Año: 2023

Publicado en: Biomedicines 11, 7 (2023), 1964 [18 pp.]
ISSN: 2227-9059

Factor impacto JCR: 3.9 (2023)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 85 / 354 = 0.24 (2023) - Q1 - T1
Categ. JCR: BIOCHEMISTRY & MOLECULAR BIOLOGY rank: 106 / 313 = 0.339 (2023) - Q2 - T2
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 65 / 189 = 0.344 (2023) - Q2 - T2

Factor impacto CITESCORE: 5.2 - Medicine (miscellaneous) (Q2) - Biochemistry, Genetics and Molecular Biology (all) (Q2)

Factor impacto SCIMAGO: 0.962 - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B56-23D

Tipo y forma: Review (Published version)

Área (Departamento): Área Fisiología (Dpto. Farmac.Fisiol.y Med.L.F.)